The Galderisi group has published several studies demonstrating senescence in mesenchymal stem cells (MSCs) from patients with RTT, partially MECP2-silenced human MSCs, MECP2-silenced human neuroblastoma cells, and heterozygous MECP2 mutant mouse mesenchymal stromal cells and neural stem cells (Squillaro et al., 2010, 2008, 2019; Mucerino et al., 2017; Alessio et al., 2018). The gene discussed is MECP2; the disease is neuroblastoma.